Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-20 00:00:00 ET · period of report 2024-02-15 · accession 0001968202-24-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-20 | 2024-02-15 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $399.66 | +172.7K | 925.2K | +23% | +$69.03M |
| D | 2024-02-20 | 2024-02-15 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $953.83 | -123.6K | 801.6K | -13% | -$117.89M |
| D | 2024-02-20 | 2024-02-15 | REGN | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $0.00 | -172.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | M | A | 172,723 | $399.66 | 925,209 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-15 | F | D | 123,601 | $953.83 | 801,608 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-02-15 | M | D | 172,723 | $0.00 | 0 | D | $399.66 · — to 2024-12-16 | 172,723 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |